Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments

　　1.Overview and Standard Dosing

　　Tivozanib(brand name FOTIVDA)is an oral targeted agent for renal cell carcinoma(RCC).Per US FDA labeling,the recommended dose is 1.34 mg orally once daily,taken for 21 consecutive days followed by 7 days off,constituting a 28-day treatment cycle.Therapy continues until disease progression or unacceptable toxicity.It may be taken with or without food.

　　2.Cyclic Dosing Schedule

　　Unlike daily continuous targeted drugs,tivozanib follows a structured“21 days on/7 days off”regimen.Patients must adhere to this cycle and should not mistake it for a daily-uninterrupted therapy.Each cycle repeats until modification or discontinuation per physician assessment.

　　3.Dose Adjustment for Hepatic Impairment

　　Moderate hepatic impairment:Reduce dose to 0.89 mg once daily,same 21/7 schedule.

　　Mild hepatic impairment:No adjustment needed.

　　Severe hepatic impairment:Avoid use;no recommended dose established.

　　4.Adverse Reaction Monitoring and Management

　　Tivozanib can induce hypertension,including hypertensive crisis;blood pressure monitoring is essential.Proteinuria,bleeding risk,and cardiovascular status also require attention.Dose interruption and/or reduction may be necessary based on type,severity,and recovery of adverse reactions.Do not self-discontinue for mild symptoms.​The 0.89 mg strength serves both as a lower dose option and the specified adjustment for moderate hepatic impairment.

　　5.Conclusion

　　Tivozanib’s intermittent schedule balances efficacy and safety.Patients should understand the cycle design,hepatic adjustment rules,and blood pressure monitoring.All dose changes must be guided by a physician.